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The competitive N-methyl-D-aspartate (NMDA) antagonist CGS 19755 
attenuates the rate-decreasing effects of NMDA in rhesus monkeys 
without producing ketamine-like discriminative stimulus effects 
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The purported competitive excitatory amino acid antagonist CGS 19755 was compared to the non-competitive 
antagonists ketamine and MK-801 in three rhesus monkeys discriminating between 1.78 mg/kg  of ketamine and saline 
while responding under a fixed-ratio 100 schedule of food presentation. MK-801 substituted completely for the 
ketamine discriminative stimulus and was 32 times more potent than ketamine as a discriminative stimulus. CGS 
19755 was studied using single and cumulative dosing procedures up to a dose of 10.0 mg/kg;  for all conditions, CGS 
19755 produced responding exclusively on the saline lever and had only modest rate-decreasing effects. N-Methyl-D- 
aspartate administered alone also did not produce ketamine-appropriate responding but did decrease response rates in 
a dose-related manner. N-Methyl-D-aspartate eliminated responding in all monkeys at doses of 5.6-10.0 mg/kg.  
MK-801 and ketamine antagonized the rate-decreasing effects of N-methyl-D-asparate, however, ketarnine was most 
effective as an antagonist at doses that decreased response rates when administered alone. CGS 19755 also attenuated 
the rate-decreasing effects of N-methyl-D-aspartate and shifted the N-methyl-D-aspartate dose-effect curve more than 
5-fold to the fight. The magnitude of antagonism of N-methyl-D-aspartate appeared to be somewhat greater with CGS 
19755 than with MK-801 or ketamine. Thus, a competitive (CGS 19755) and some non-competitive (MK-801 and 
ketamine) excitatory amino acid antagonists can attenuate the rate-decreasing effects of N-methyl-D-aspartate. 
Surprisingly, the results suggest that antagonism of N-methyl-D-aspartate is not sufficient to produce ketamine-like 
discriminative stimulus effects under these conditions in rhesus monkeys. 
NMDA (N-methyl-D-aspartate); MK-801; CGS 19755 (1-(cis-2-carboxypiperidine-4-yl)-methyl-l-phosphonic acid); 
Schedule-controlled responding; Drug discrimination; (Rhesus monkey) 
1. Introduction 
I t  has been  p r o p o s e d  that  exc i ta tory  amino  ac id  
( E A A )  neuro t ransmiss ion  is an i m p o r t a n t  neuro-  
chemica l  sys tem med ia t ing  the behaviora l  effects 
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of  phencyc l id ine  (PCP)- l ike  drugs  (e.g. K o e k  and  
Woods ,  1988). There  is a cons ide rab le  a m o u n t  of  
evidence tha t  suppor t s  the no t ion  tha t  a n t a gon i sm  
at N - m e t h y l - D - a s p a r t a t e  ( N M D A ) - a s s o c i a t e d  ion 
channels  is one mechan i sm of  ac t ion  of  PCP- l ike  
drugs  in vitro,  however,  there  has  been  l i t t le  d i rec t  
evidence regard ing  in te rac t ions  be tween  N M D A  
and  p re sumed  N M D A  an tagon i s t s  in vivo. The  
presen t  s tudy  was des igned to c o m p a r e  the  behav-  
iora l  effects of  a p u r p o r t e d  sys temat ica l ly  act ive 
compet i t ive  N M D A  an tagon i s t  C G S  19755 ( ( + ) -  
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5-methyl-10,11-dihydro-5 H-dibenzo(a,d)cyclohep- 
ten-5,10-amine maleate; Lehmann et al., 1987) to 
those of the non-competitive NMDA antagonists 
MK-801 (1-(cis-2-carboxypiperidine-4-yl)methyl- 
1-phosphonic acid; Wong et al., 1986) and keta- 
mine. The behavioral imphcations of the differ- 
entiation between competitive and non-competi- 
tive antagonists, as defined electrophysiologically, 
is a relatively unexplored area of research (e.g. 
Koek and Woods, 1987). 
The discriminative stimulus effects of ketamine 
are well characterized, and it has been shown that 
a wide variety of compounds (e.g. PCP) that share 
other behavioral effects (e.g. anesthesia) with 
ketamine also substitute for the ketamine dis- 
criminative stimulus (Balster and Willetts, 1988; 
Koek et al., 1988). Recently the non-competitive 
N M D A  antagonist MK-801 (Wong et al., 1986) 
has been shown to share discriminative stimulus 
effects with ketamine and with PCP. MK-801 
substituted completely for the PCP discriminative 
stimulus in rats (Willetts and Balster, 1988a) and 
in pigeons (Koek et al., 1988) but substituted 
partially (65-85%) for ketamine in rhesus monkeys 
(Koek et al., 1988). Perhaps due to their poor 
availability centrally when administered systemi- 
cally, competitive N M D A  antagonists have not 
been studied extensively in primates (Woods et al., 
1987). In the present study the discriminative 
stimulus effects of the purported competitive EAA 
antagonist CGS 19755 (Bennett et al., 1987; Boast 
et al., 1987; Lehmann et al., 1987) were assessed 
in rhesus monkeys discriminating between sub- 
cutaneous (s.c.) injections of ketamine and saline. 
Ketamine, MK-801, and CGS 19755 were also 
compared for their capacity to attenuate the rate- 
decreasing effects of NMDA. 
2. Materials and methods 
2.1. Subjects 
Three adult, male rhesus monkeys (Macaca 
mulatta) trained previously to discriminate be- 
tween s.c. injections of 1.78 mg /kg  of ketamine 
and saline were housed individually with free 
access to water. In addition to food received dur- 
ing experimental sessions, monkeys received 
Purina Monkey Chow and fresh fruit post-session 
in the home cage. 
2.2. Apparatus 
During experimental sessions monkeys were 
seated in Plexiglas primate chairs located inside 
ventilated, sound-attenuating chambers provided 
with continuous white noise. On one wall of the 
chamber were located an array of stimulus lights 
as well as two response levers and a food re- 
ceptacle that were within easy reach of a seated 
monkey. A food hopper was mounted on the 
outside of the chamber and delivered food (300 
mg Noyes banana-flavored pellets) to a receptacle 
via a plastic tube. Experiments were controlled 
and data recorded with microprocessors (IBM 
PCjr). 
2.3. Procedure 
Sessions of 0.5-1.5 h were conducted five days 
per week and consisted of 2-6 discrete, 15-min 
cycles. Each cycle consisted of a 10-min time out 
during which the chamber was dark and lever 
presses had no programmed consequence, and a 
5-min response period during which the chamber 
was illuminated by pairs of 7 W blue and green 
lights and food was available under a fixed-ratio 
(FR) 100 schedule. Completion of 100 lever presses 
on the injection-appropriate lever (left lever, 
ketamine-appropriate;  right lever, saline-ap- 
propriate) resulted in delivery of 10 food pellets. 
An incorrect response reset the FR requirement to 
100 for the correct lever. Injections of drug or 
saline were made during the first minute of the 
10-min time out. The training dose of ketamine 
was injected only once per day and that cycle was 
preceded by 0-4 saline-injection cycles. For some 
training sessions ketamine was not administered 
and monkeys received an injection of saline prior 
to each of 2-6 cycles. 
Test sessions were conducted every 2-3 days so 
long as stimulus control was maintained in the 
intervening training sessions according to the 
criteria: fewer than 100 responses on the incorrect 
lever and at least 90% of responses on the correct 
lever for all cycles. Test sessions were identical to 
training sessions except that 100 consecutive 
responses on either lever produced food and vari- 
ous doses of other drugs were administered during 
the first minute of each time out. For some studies 
increasing doses of drug were administered over 
successive cycles (i.e. cumulative dosing) and for 
other studies a single dose of drug was adminis- 
tered 0-24 h prior to the beginning of a test 
session. 
CGS 19755 was compared to MK-801 and 
ketamine using two behavioral endpoints. First, 
the capacity of CGS 19755 and MK-801 to sub- 
stitute for the ketamine discriminative stimulus 
was studied. Second, the capacity of CGS 19755, 
MK-801 and ketamine to antagonize the effects of 
N M D A  on FR responding for food was also 
studied in the same monkeys. The experimental 
conditions for antagonism studies were the same 
as substitution studies with single doses of each 
antagonist administered prior to increasing doses 
of NMDA. Based upon results of preliminary 
drug discrimination studies the pretreatment time 
was 15 rain for ketamine, 30 rain for MK-801 and 
2 h for CGS 19755. (These are the times for 
MK-801 and ketamine at which ketamine-ap- 
propriate responding occurred reliably. CGS 19755 
failed to produce ketamine-appropriate respond- 
ing and for studies of antagonism it was adminis- 
tered 15 min-24 h prior to NMDA.) 
2.4. Data analysis 
Drug discrimination data are expressed as the 
average percentage of responses on the ketamine- 
appropriate lever for three monkeys. Drugs were 
considered to have substituted for ketamine if 
they produced at least 90% ketamine-appropriate 
responding. Response rate data are the average 
rates of responding among the three monkeys and 
are expressed as a percentage of the control (saline) 
response rate. These values were determined for 
individual subjects by dividing the response rate 
during test sessions by the average control re- 
sponse rate of 20 training cycles preceded by 
injections of saline and multiplying by 100. 
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2.5. Drugs 
The drugs used in this study were ketamine 
hydrochloride (Ketalar, Warner-Lamber t /Parke-  
Davis), MK-801 ((+)-5-methyl-10,11-dihydro- 
5 H-dibenzo(a,d)cyclohepten-5,10-imine maleate; 
Merck, Sharp and Dohme, Westpoint, PA), CGS 
19755 (1-(cis-2-carboxypiperidine-4-yl)methyl-1- 
phosphonic acid; synthesized by P. Ornstein), and 
N MD A  (N-methyl-D-aspartate; Sigma Chemical 
Co., St. Louis, MO). MK-801, CGS 19755 and 
NMDA were dissolved in sterile water. Sterile 
water also was used for diluting Ketalar solutions. 
All drugs were administered s.c. in the back and 
doses are expressed in terms of the salts (mg/kg  
body weight). Injection volumes were 0.1 m l /k g  
for ketamine, MK-801 and N M D A  and 0.1-0.4 
ml /kg  for CGS 19755. 
3. Results 
Single injections of ketamine or MK-801 pro- 
duced responding on the ketamine-appropriate 
lever in a dose-related manner and at larger doses 
decreased rates of responding maintained by the 
presentation of food (fig. 1). MK-801 was 32 times 
more potent than ketamine as a discriminative 
stimulus and 10-32 times more potent than keta- 
mine in decreasing response rates. Various doses 
of CGS 19755 were studied using a variety of 
pretreatments using single and cumulative dosing 
procedures, and under no condition did CGS 
19755 substitute for ketamine. For example, single 
doses of CGS 19755, up to a dose of 10.0 mg/kg,  
produced responding exclusively on the saline lever 
and decreased rates of responding to 61% of con- 
trol (fig. 1). 
N M D A  (1.0-10.0 mg/kg)  produced no keta- 
mine-appropriate responding (data not shown) and 
no observable behavioral effects up to doses that 
decreased rates of food-maintained responding 
(closed symbols, fig. 2). A dose of 1.0 m g / k g  of 
N MD A  did not affect response rates whereas a 
dose of 5.6 m g /k g  of N MD A  eliminated respond- 
ing in two monkeys and the third monkey failed 
to respond at a dose of 10.0 m g /k g  NMDA. The 
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Fig. 1. Dose effect curves for ketamine, MK-801 and CGS 
19755 in rhesus monkeys discriminating between 1.78 mg/kg 
of ketamine and saline. Each point is the average of single 
determinations in each of three subjects. A single injection was 
administered immediately before (ketamine) or 15 min before 
(MK-801 and CGS 19755) the beginning of a test cycle. 
Ordinates: upper panel, average percentage of responses on the 
ketamine lever_+ 1 S.E.M.; lower panel, average response rate 
expressed as a percentage of the control (saline) response 
rate_+1 S.E.M. The average control response rates over 20 
saline cycles for individual monkeys were 3.42_+0.11, 1.91_+ 
0.26 and 2.99 _+ 0.37. Abscissas: dose in mg/kg body weight. 
discriminative stimulus effects of ketamine and 
MK-801 were not altered by N M D A  and, there- 
fore, only response rate data are presented from 
the antagonism studies. Doses of ketamine that 
decreased response rates when administered alone 
attenuated the rate-decreasing effects of N M D A  
(left panel, fig. 2). These doses of ketamine (1.0, 
1.78 and 3.2 m g / k g )  did not alter markedly the 
rate-decreasing effects of a dose of 3.2 m g / k g  of 
N M D A  but did attenuate the effects of larger 
doses of N M D A  such that doses larger than 5.6 
m g / k g  of N M D A  were required to eliminate re- 
sponding. A dose of 5.6 m g / k g  of ketamine 
eliminated responding and this effect was not 
altered by the administration of 1.0 m g / k g  of 
NMDA.  
In contrast to the results obtained with keta- 
mine, doses of MK-801 that did not decrease 
response rates attenuated the rate-decreasing ef- 
fects of N M D A  (center panel, fig. 2). Doses of 
0.01 and 0.032 m g / k g  of MK-801 did not de- 
crease response rates when administered alone 
and shifted the dose-effect curve for N M D A  0.25 
and 0.5 log units to the right, respectively. A dose 
of 0.056 m g / k g  of MK-801 decreased response 
rates to approximately 50% of control rates; this 
dose of MK-801 administered in combination with 
1.0 m g / k g  of N M D A  eliminated responding in all 
three monkeys. 
CGS 19755 attenuated the rate-decreasing ef- 
fects of N M D A  in a dose- and time-related 
manner. When administered 2 h prior to increas- 
ing doses of NMDA,  doses of 0.1 and 1.0 m g / k g  
of CGS 19755 antagonized the rate-decreasing 
effects of N M D A  and shifted the N M D A  dose-ef- 
fect curve in parallel to the right (right panel, fig. 
2). Whereas under control conditions responding 
was eliminated by a dose of 5.6 m g / k g  of NMDA,  
2 h after 1.0 m g / k g  of CGS 19755 this dose of 
N M D A  had no effect on response rates and a 
3-fold larger dose of N M D A  (17.8 m g / k g )  was 
required to eliminate responding. A larger dose of 
CGS 19755, 3.2 mg /kg ,  did not produce ad- 
ditional antagonism of the rate-decreasing effects 
of NMDA.  
The antagonistic actions of CGS 19755 were 
studied 15 rain-24 h after administration of 3.2 
m g / k g  of CGS 19755. Antagonism of the rate-de- 
creasing effects of N M D A  by CGS 19755 was 
greater when CGS 19755 was administered 15 min 
prior to N M D A  than when longer pretreatment 
intervals were used (fig. 3). While a dose of 17.8 
m g / k g  of N M D A  eliminated responding 2 h after 
administration of 3.2 m g / k g  of CGS 19755, this 
dose of N M D A  had no effect on response rates 
when CGS 19755 was administered 15 min prior 
to NMDA.  Only a slight attenuation of the rate- 
decreasing effects of N M D A  was observed 24 h 
after administration of a dose of 3.2 m g / k g  of 
CGS 19755. 
4. Discussion 
Monkeys discriminating between s.c. injections 
of ketamine and saline generalized to the non- 
competitive EAA antagonist MK-801 but did not 
generalize to the competitive EAA antagonist CGS 
19755 up to a dose of 10.0 mg/kg.  These data 
confirm previous reports on the discriminative 
stimulus effects of MK-801 in monkeys and other 
species (Koek et al., 1988; Willetts and Balster, 
1988a) and extend results from a study in which 
another  competitive EAA antagonist, AP5 
(Watkins and Evans, 1981), failed to substitute for 
the ketamine discriminative stimulus when given 
systemically in monkeys (Woods et al., 1987). 
Results of the present study also are consistent 
with previous demonstrations (e.g. Willetts and 
Balster, 1988b) on the lack of antagonism by 
NMDA of the discriminative stimulus effects of 
non-competitive antagonists. 
The pretreatment times for ketamine and MK- 
801 used in the NMDA antagonism study were 
selected so as to be able to compare these com- 
pounds at a time when they produced unequivocal 
ketamine-like discriminative stimulus effects. Full 
substitution (i.e. > 90%) for the ketamine dis- 
criminative stimulus obtained with MK-801 in the 
present study using a 30-min pretreatment sug- 
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Fig. 3. Rate-decreasing effects of  cumulative doses of N M D A  
administered alone (closed symbols) and when administered 15 
min, 2 h and 24 h after administration of 3.2 m g / k g  of CGS 
19755. Data  points above S represent the effects of saline after 
pretreatment with CGS 19755. See fig. 1 for other details. 
gests the partial substitution reported for keta- 
mine in a previous report (Koek et al., 1988) 
might have resulted from the temporal conditions 
used to study discriminative stimulus effects (i.e. 
10-min pretreatment). Because CGS 19755 did not 
produce ketamine-appropriate responding, it was 
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these testing conditions. Based upon preliminary 
studies in pigeons (S. Baron, personal communica- 
tion) that indicated a slow onset of action for 
CGS 19755, a 2 h pretreatment was used initially 
with CGS 19755 in rhesus monkeys. It is clear, 
however, from the time course study with a dose 
of 3.2 mg/kg of CGS 19755 that antagonism of 
the rate-decreasing effects on NMDA can be ob- 
tained within 1 h of administration of CGS 19755. 
While it is possible that doses of CGS 19755 larger 
than 10.0 mg/kg might produce ketamine-ap- 
propriate responding, it is clear that doses of CGS 
19755 and MK-801 (0.01 mg/kg) that did not 
produce ketamine-appropriate responding at- 
tenuated the behavioral effects of NMDA. More- 
over, the rate-decreasing effects obtained with a 
dose of 10.0 mg/kg of CGS 19755 suggest larger 
doses of CGS 19755 might decrease further or 
eliminate food-maintained responding. 
CGS 19755 clearly antagonizes the behavioral 
actions (e.g. rate-decreasing effects) of NMDA in 
rhesus monkeys and this effect probably indicates 
that systemically administered CGS 19755 accesses 
NMDA receptors in brain. However, under condi- 
tions in which CGS 19755 antagonizes the rate-de- 
creasing effects of NMDA it does not produce 
discriminative stimulus effects comparable to 
MK-801, ketamine and other non-competitive 
NMDA antagonists. Further studies might dem- 
onstrate similarities in the discriminative stimulus 
effects of competitive and non-competitive NMDA 
antagonists, however, in the absence of evidence 
in support of this notion, it might be supposed 
that in humans the subjective effects of non-com- 
petitive NMDA antagonists will be different from 
the subjective effects of competitive antagonists. 
The lack of ketamine-like discriminative stimulus 
effects of CGS 19755 raises interesting questions 
regarding the conditions under which competitive 
N M D A  a n t a g o n i s t s  c a n  be  u s e d  to  m a i n t a i n  d i s -  
criminative control and the relation of these train- 
ing conditions to conditions wherein the same 
antagonists prevent the behavioral actions of 
NMDA. Competitive antagonists at opioid recep- 
tors (e.g. naltrexone) can be utilized over a large 
range of non-discriminable doses to prevent the 
behavioral effects of opioid agonists (France and 
Woods, 1985; 1988). 
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